Payment of tradable shares by Kevin Yankton of Twist Bioscience subject to Rule 16b-3

TWST Stock  USD 45.12  0.50  1.10%   
Slightly above 62% of Twist Bioscience's investor base is looking to short. The analysis of the overall investor sentiment regarding Twist Bioscience Corp suggests that many traders are alarmed. Twist Bioscience's investing sentiment can be driven by a variety of factors including economic data, Twist Bioscience's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Twist Bioscience Corp officer. Payment of exercise price or tax liability by delivering or withholding securities

Read at macroaxis.com
Twist insider trading alert for payment of common stock by Kevin Yankton, Chief Accounting Officer, on 12th of April 2023. This event was filed by Twist Bioscience Corp with SEC on 2023-04-12. Statement of changes in beneficial ownership - SEC Form 4

Twist Bioscience Fundamental Analysis

We analyze Twist Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Twist Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Twist Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Twist Bioscience is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Twist Bioscience Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Twist Bioscience stock to make a market-neutral strategy. Peer analysis of Twist Bioscience could also be used in its relative valuation, which is a method of valuing Twist Bioscience by comparing valuation metrics with similar companies.

Peers

Twist Bioscience Related Equities

CDNACaredx   5.63   
0%
88.0%
NTRANatera   3.64   
0%
57.0%
CSTLCastle Biosciences   1.71   
0%
26.0%
GHGuardant Health   1.22   
0%
19.0%
IQVIQVIA Holdings   0.82   
0%
12.0%
ILMNIllumina   0.43   
0%
6.0%
TMOThermo Fisher   0.13   
2.0%
0%
AAgilent Technologies   0.30   
4.0%
0%
DHRDanaher   0.42   
6.0%
0%
MTDMettler Toledo   0.68   
10.0%
0%
EXASEXACT Sciences   0.74   
11.0%
0%
WATWaters   0.75   
11.0%
0%
ICLRICON PLC   1.46   
22.0%
0%
PSNLPersonalis   6.35   
100.0%
0%

Additional Tools for Twist Stock Analysis

When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.